Legend Biotech Corp Stock Price, News & Analysis

Exelixis, Inc. (Nasdaq: EXEL) announced that Carl Feldbaum and Vincent Marchesi will not seek re-election to the Board of Directors during the 2023 Annual Meeting of Stockholders. The Board is nominating Tomas Heyman and Robert Oliver as independent directors to fill their positions. This decision follows unsuccessful settlement negotiations with Farallon Capital Management regarding board member nominations and access to company information. Dr. Stelios Papadopoulos expressed gratitude toward Feldbaum and Marchesi for their service. The upcoming board election aims to enhance corporate governance. Following the election, the Board will consist of 11 members, 10 of whom are independent. The Annual Meeting date has yet to be announced.

Legend Biotech Corporation (NASDAQ: LEGN) has appointed Mythili Koneru, M.D., Ph.D. as its new Chief Medical Officer. Dr. Koneru previously served at Marker Therapeutics where she led the development of cell therapies and peptide vaccines. Her extensive background includes roles at Eli Lilly, focusing on immuno-oncology clinical development, and an oncology fellowship at Memorial Sloan-Kettering Cancer Center. CEO Ying Huang expressed confidence in Dr. Koneru's expertise in immunotherapy and cell therapy, emphasizing her role in advancing the company's pipeline. Dr. Koneru holds a B.A. in Cellular and Molecular Biology from the University of Chicago, a Ph.D. in Tumor Immunology from New York University, and an M.D. from Robert Wood Johnson Medical School.

The report titled "Global Royalty Rate Trends in Pharma and Biotech Dealmaking 2010-2023" has been released by ResearchAndMarkets.com. This comprehensive report offers insights into partnering deals in the pharmaceutical and biotechnology sectors, including details on technology licensed, royalty rates, license fees, and other payments. It covers all disclosed deals since 2010, providing essential data for prospective dealmakers. Key chapters analyze royalty rate trends, the structure of royalty clauses, and leading companies in the field. The report aims to equip readers with the necessary tools for effective negotiations and due diligence in licensing agreements.

The CAR-T Therapy Pipeline Analysis Global Market Report 2023 has been released by ResearchAndMarkets.com, detailing significant growth in the CAR-T therapy market. The market is projected to expand from $1.40 billion in 2021 to $1.80 billion in 2022, reflecting a CAGR of 28.6%. By 2026, the market is expected to reach $3.55 billion, growing at a CAGR of 18.5%. Major players include Legend Biotech, Novartis AG, and Kite Pharma. The report highlights the role of financial support for CAR-T therapy development and notes the impact of high costs and limitations in treating certain cancers as challenges. The leading regions are North America and Western Europe, while the main product types include monotherapy and combination therapy targeting cancers such as acute lymphoblastic leukemia.